Acute sunitinib neurotoxicity

dc.authorscopusid57201646266
dc.authorscopusid23004395600
dc.authorscopusid6505910645
dc.authorscopusid10144082400
dc.contributor.authorGULMEZ A.
dc.contributor.authorDIKILITAS M.
dc.contributor.authorELKIRAN E.T.
dc.contributor.authorHARPUTLUOGLU H.
dc.date.accessioned2024-08-04T20:03:41Z
dc.date.available2024-08-04T20:03:41Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractSunitinib malate is a multitargeted oral tyrosine kinase inhibitor (TKI) which is used in treatment of metastatic renal cell carcinoma with side effects such as diarrhea, mucositis, asthenia and myelosuppression. Serious toxicity associated with sunitinib is a rare situation. However; there are few cases reported in the literature. As a result of the inhibition that is caused by sunitinib malate agent at the receptor level, vascular endothelial growth factor (VEGF) level increases. These increased VEGF levels are considered to having a positive contribution on neurological side effects. Neurotoxicity that is related with the usage of sunitinib malate for two weeks will be presented in this case report. © 2021 The Author(s)en_US
dc.identifier.doi10.1016/j.ctarc.2021.100366
dc.identifier.issn2468-2942
dc.identifier.pmid33812180en_US
dc.identifier.scopus2-s2.0-85104956589en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.ctarc.2021.100366
dc.identifier.urihttps://hdl.handle.net/11616/92023
dc.identifier.volume27en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Ltden_US
dc.relation.ispartofCancer Treatment and Research Communicationsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNeurotoxicityen_US
dc.subjectRenal cell canceren_US
dc.subjectTyrosine Kinase Inhibitoren_US
dc.titleAcute sunitinib neurotoxicityen_US
dc.typeArticleen_US

Dosyalar